Collegium Pharmaceutical

Collegium Pharmaceutical, Inc. operates as a pharmaceutical company. The firm engages in the development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta IR is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Collegium Pharmaceutical reports record 2022 performance and outlines growth strategies

Collegium Pharmaceutical's strong 2022 performance and strategic acquisitions position it for continued success in 2023 with a focus on growth.
The company's commercial strengths in key products like BELBUCA and Xtampza ER drive revenue and showcase growth potential.
Challenges in managing leverage, accelerating franchise growth, and navigating market dynamics are balanced by opportunities for expansion and innovation.
Analysts' inquiries reflect interest in Collegium Pharmaceutical's strategies, market positioning, and response to regulatory changes for future growth.

Collegium Pharmaceutical reports record Q1 revenue amidst patent challenges

Collegium Pharmaceutical's Q1 2023 performance showcased record revenue and strong financial management strategies.
The company faces challenges from patent infringement risks and generic competition, requiring a focus on defending IP and market positioning.
Opportunities in volume growth, business development, and strategic investments in key products position Collegium for long-term success.
Maintaining a balance between defending IP, managing expenses, and driving growth will be crucial for Collegium's future performance.

Collegium Pharmaceutical posts record revenue and growth, eyes strategic acquisitions

Collegium Pharmaceutical reported strong financial performance in Q2 2023, with a focus on achieving a banner year. Despite challenges with Xtampza ER and growth expectations, the company remains committed to improving access, reducing debt, and returning capital to shareholders.

Collegium Pharmaceutical excels in Q3, eyes growth opportunities ahead

Collegium Pharmaceutical reports strong Q3 2023 performance with record revenue and EBITDA growth, driven by successful contract renegotiations and operational efficiency.
Challenges include mitigating declining scripts, navigating patient profiles, and sustaining growth amidst market uncertainties, requiring strategic adjustments and foresight.
Opportunities lie in Medicare Part D market expansion, differentiated asset focus, and strategic valuations, positioning Collegium for future growth and market leadership.

Collegium Pharmaceutical reports record revenue and strategic wins in pain management market

Collegium Pharmaceutical's Q4 2023 earnings call highlighted exceptional financial achievements, robust product performance, and strategic wins in the pain management market. While facing challenges in maintaining guidance and addressing analyst queries, the company remains optimistic about its future outlook and growth potential.

Collegium Pharmaceutical reports strong Q1 earnings amidst leadership transition

Collegium Pharmaceutical's Q1 2024 earnings call highlighted strong financial performance, leadership transition, and growth strategies.
Despite challenges such as CEO resignation and competitive landscape dynamics, the company remains focused on its market position and growth potential.
Opportunities for business development priorities and strategic partnerships offer avenues for future growth and expansion.

Collegium Pharmaceutical reports record Q3 performance and navigates market challenges

Collegium Pharmaceutical's Q3 performance showcased robust financial results and strategic moves to strengthen their market position. While facing challenges in formulary changes and market competition, the company is well-positioned to leverage opportunities in the ADHD market and drive continued growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.

Collegium Pharmaceutical Inc (NASDAQ: COLL) reported Q2 adjusted EPS of $0.27, below the consensus of $0.36. The reported EPS of $1.79 was up from $0.23 a year ago and included a one-time non-cash adjustment of $1.52 per share.

Collegium Stock Is Getting Beaten As Q2 Earnings Miss Street Estimates; Revises FY21 Guidance

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -20.59% and -1.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Miss Estimates

– Xtampza ® ER Market Share Grew to 31.5% of the Oxycodone Extended-Release Market in June 2021 –

Collegium Reports Strong Q2 Results with Cash Balance Growing to Over $200 Million

STOUGHTON, Mass., July 21, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live webcast on Thursday, August 5, 2021, at 4:30 p.m. Eastern Time. The Company will discuss its financial results and provide a corporate update.

Collegium to Host Conference Call to Discuss Second Quarter 2021 Financial Results and Provide Corporate Update

Collegium Pharmaceutical continues to move closer to achieving their mission of becoming the market leader in responsible pain management. Collegium reported a strong beat on their Q1 EPS and revenue. Xtampza ER is rapidly accruing market share and record all-time highs in total prescriptions, new-to-brand, and market share, and total prescribers in the quarter.

Collegium Pharmaceutical: Moving Closer To The Top

STOUGHTON, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced a publication titled, “Nonmedical Use of Xtampza® ER and Other Oxycodone Medications in Adults Evaluated for Substance Abuse Treatment: Real-world Data from the Addiction Severity Index – Multimedia Version (ASI-MV®),” was published in the peer-reviewed medical journal, Journal of Pain Research.

Collegium Announces Publication of Real-World Data in Journal of Pain Research

Heron Therapeutics

The White House's plans to address the U.S. opioid crisis could be good news for Heron Therapeutics and Collegium Pharmaceutical, makers of safer pain management drugs.

Under Biden's Budget, These 2 Little-Known Biotechs Could Help End the Opioid Crisis

STOUGHTON, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conference:

Collegium to Participate in Upcoming Investor Conference

Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q1 2021 Results - Earnings Call Transcript

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 36.67% and 8.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Collegium Pharmaceutical (COLL) Beats Q1 Earnings and Revenue Estimates

– Net Income of $15.7 Million and Adjusted EBITDA of $45.3 Million in the First Quarter of 2021 –

Collegium Reports Record Quarterly Revenue of $87.7 Million

STOUGHTON, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, May 6, 2021 at 4:30 p.m. Eastern Time. The Company will discuss its financial results and provide a corporate update.

Collegium to Host Conference Call to Discuss First Quarter 2021 Financial Results and Provide Corporate Update

Despite the COVID -19 pandemic, Collegium Pharmaceutical had an impressive 2020. The company recorded a full year of profitability and commercial progress. Collegium is off to a good start in 2021, with the company reporting Xtampza ER's quarter-to-date total script volume being up 13% over Q4.

Collegium Pharmaceutical: No Longer Speculative After A Year Of Profitability

Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q4 2020 Results - Earnings Call Transcript

– 2020 First Full-Year of Profitability, Driven by Xtampza ® ER Revenue Growth and the Nucynta ® Acquisition –

Collegium Reports Record Full-Year 2020 Revenue of $310.0 Million

STOUGHTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, February 25, 2021 at 4:30 p.m. Eastern Time. The Company will discuss its financial results and provide a corporate update.

Collegium to Host Conference Call to Discuss Fourth Quarter 2020 Financial Results and Provide Corporate Update

It's not every day that a company graduates to a slot in a high-profile stock index.

Why Collegium Pharmaceutical Rose Nearly 10% on Tuesday

– Xtampza ® ER Revenues Expected in the Range of $155.0 million to $165.0 million –

Collegium Provides 2021 Financial Guidance

Collegium Pharmaceutical recently reported their Q3 earnings with a beat on EPS and revenue. Despite some serious COVID-19 headwinds, Collegium was able to record another quarter of growth and increase their cash on hand while paying down debt.

Collegium Pharmaceutical: Another Quarter Of Record Revenue Reinforces Long Thesis

Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q3 2020 Results - Earnings Call Transcript

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 39.13% and 1.61%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Collegium Pharmaceutical (COLL) Tops Q3 Earnings and Revenue Estimates

Athenex

These two companies aren't reinventing the wheel, but they still have the potential for tremendous growth.

Investing $5,000 in These 2 Biotechs Could Make You Rich

STOUGHTON, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time. The Company will discuss its financial results and provide a corporate update.

Collegium to Host Conference Call to Discuss Third Quarter 2020 Financial Results and Provide Corporate Update

Inmode Ltd

Pfizer

These three health-related businesses are well positioned to provide market-beating gains.

3 Top Healthcare Stocks You Can Buy Now for Less Than $40

STOUGHTON, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that it has reached a settlement agreement with Teva Pharmaceutical USA, Inc. (Teva) that resolves patent litigation brought in response to Teva’s Abbreviated New Drug Application (ANDA), seeking approval to market a generic version of Xtampza ER prior to the expiration of Collegium’s applicable patents.

News for Collegium Pharmaceutical Stock (COLL)